🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution

Recruitingn/aAges 18 Years - anyAllRoyal Marsden NHS Foundation Trust
NCT07084571 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

FORTITUDE is a translational research study that aims to collect serial multi-site needle biopsy samples of tumour tissue and blood from metastatic breast cancer patients. Cancer biopsies are generally performed when cancer is diagnosed and are sometimes repeated when the cancer is suspected to have spread but this is not mandatory. However, studies have shown that cancers change with time and evolve to become resistant to therapy. The purpose of this study is to assess the feasibility of biopsies of multiple cancer sites across different time points during treatment and understand how cancers evolve and change throughout treatment. The findings of this study could pave the way for using cancer biopsies more frequently in the clinic to pick up changes in cancer behaviour that could influence treatment choice. The samples collected from this study will be used for molecular and genetic re

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Histologically confirmed locally advanced, inoperable breast cancer or metastatic breast cancer OR radiological evidence of metastatic disease with a high index of suspicion that this is a recurrence of a previously diagnosed breast cancer. 2. Be aged 18 years and over. 3. Have given written informed consent to participate. Exclusion Criteria: 1. Metastatic disease limited to bones, without a soft tissue component. 2. Any bleeding disorders or anticoagulation that cannot be corrected and that would render the risk of biopsy unacceptable. 3. If the consultant physician involved in the care of the patient assesses and decides the risk of the biopsy procedures is significant, defined as greater than 1% risk of significant complication. 4. Eastern Cooperative Oncology Group performance status of 3 and higher. 5. Known chronic infectious disease (Hepatitis B and C, HIV) that may impact patient safety. 6. Presence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule.
💊

What it tests

  • Not listed
📍

Where

1 site
Royal Marsden NHS Foundation Trust
London, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy